Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
James Thomas · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · 2023 · $9,722,540 — Over the last year, NISC operated the following suite of production sequencing machines: 2 PacBio Sequel II, 1 Illumina NovaSeq 6000, 1 Oxford Nanopore GridION, 1 Oxford Nanopore P24 PromethION, and 4 Illumina MiSeqs. Using these platforms, we have generated over 3,222 billion reads in the past year…
Raymond Paul Goodrich · COLORADO STATE UNIVERSITY · 2023 · $1,338,439 — Project Summary: The BSL3 suites in the Rocky Mountain Regional Biocontainment Laboratory (RMRBL) at Colorado State University (CSU) have been operational and at capacity since being commissioned. These facilities support research in response to new threats from established pathogens, such as Mycoba…
Ighovwerha Ofotokun · EMORY UNIVERSITY · 2023 · $525,581 — PROJECT SUMMARY/ABSTRACT The Clinical Research Core (CRC) (Core D) provides services to support researchers conducting human subjects research studies investigating the pathogenesis of HIV disease, treatment and prevention of HIV, strategies to eliminate HIV from those who are infected, and the re…
Daniel E Voth · UNIV OF ARKANSAS FOR MED SCIS · 2023 · $228,000 — PROJECT SUMMARY/ABSTRACT A primary means of research support for investigators in the Center for Microbial Pathogenesis and Host Inflammatory Responses (CMPHIR) in Phase III will be the NIGMS-funded Pilot Grant Program (PGP), supplemented with institutional funds ($100,000 per year for each year) t…
Stephen Mark Tompkins · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $390,290 — Summary/Abstract Robust animal models of coronavirus infection are required for pre-clinical assessment of candidate vaccines and therapeutic antibodies to prevent coronavirus infection and disease. The goal of the Animal Model Core is to provide a central resource of animal models and virological t…
Olivier Elemento · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · 2023 · $135,600 — Data Management Core Principal Investigator: Olivier Elemento, PhD. Co-I: Zhengming Chen, PhD Abstract This Core will provide bioinformatics expertise and support with data integration and analyses. The Core will serve three main goals. First, it will provide central data storage and data management…
RICHARD G WUNDERINK · NORTHWESTERN UNIVERSITY AT CHICAGO · 2023 · $234,154 — PROJECT SUMMARY CORE B Lower respiratory tract infections cause nearly 80% of deaths from infectious diseases in the US, and respiratory viruses, such as influenza and SARS-CoV-2, are increasingly recognized as common causes of severe community-acquired pneumonia (CAP). As mortality from severe CAP …
ASIMAH RAFI · TECHNICAL RESOURCES INTERNATIONAL, INC. · 2023 · $5,439,404 — The purpose of this contract is to provide regulatory expertise and support to operate and manage the NIAID Regulatory Support Center (RSC) to provide a wide range of clinical research activities and programs for NIAID. The RSC provides comprehensive regulatory support to: 1) perform NIAID-funded an…
TIMOTHY STEDMAN · AMERICAN TYPE CULTURE COLLECTION · 2023 · $1,864,880 — This contract provides unique and quality-assured infectious reagents and resources to the scientific community for use in basic research and product development. The scope of this contract includes the acquisition, authentication, production, preservation, storage, and distribution of research and …
TIMOTHY STEDMAN · AMERICAN TYPE CULTURE COLLECTION · 2023 · $1,647,582 — This contract provides unique and quality-assured infectious reagents and resources to the scientific community for use in basic research and product development. The scope of this contract includes the acquisition, authentication, production, preservation, storage, and distribution of research and …
Julie A. Ake · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2022 · $42,798 — Abstract COVID-19 Vaccine Clinical Development Team The USG enterprise to develop and optimize vaccine prevention modalities for SARS CoV-2 incorporates the DAIDS HVTN as a key partner in strategic development, research prioritization and execution, landscape analysis for future directions and analy…
Lisa Jenkins · DIVISION OF BASIC SCIENCES - NCI · 2019 · $418,689 — Overall, the expertise of the Mass Spectrometry Unit is being widely used to further the research of multiple groups within the NIH. In FY2019, the unit collaborated in 67 different projects, with more than 3000 samples processed and analyzed. These projects are being performed in collaboration with…
Pamela J Bjorkman · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2019 · $410,750 — Summary The rapid mutation rate of HIV-1 results in many thousands of viral strains, thus thwarting current vaccine efforts. Although HIV-1 infection can be controlled by anti-retroviral therapy (ART), the virus rebounds within weeks of ART cessation because complete elimination of HIV-1 is prevente…
HEATHER R DESAIRE · UNIVERSITY OF KANSAS LAWRENCE · 2019 · $671,763 — DESCRIPTION (provided by applicant): Preventing human immunodeficiency virus (HIV-1) transmission by vaccination is a highly desirable, but elusive, goal. Vaccine-induced antibodies that bind the HIV-1 envelope glycoprotein (Env) spike and neutralize the virus are thought to be a desirable comp…
JANICE P EVANS · PURDUE UNIVERSITY · 2019 · $77,500 — PROJECT SUMMARY Actin cytoskeleton-based processes play crucial roles in meiosis in mammalian oocytes, including positioning of the meiotic spindle and asymmetric cell division. These events in oocytes are essential for reproductive success, as gene knockouts that impair these processes cause femal…
Vaughn Vasil Smider · APPLIED BIOMEDICAL SCIENCE INSTITUTE · 2019 · $359,955 — Vaccines are the primary means by which to prevent, control, or eradicate infectious diseases. While many vaccines have been successfully developed and have resulted in enormous medical and veterinary benefit, there are certain viruses that have eluded effective vaccine development. Generally, virus…
quaisar Ali · ANGION BIOMEDICA CORPORATION · 2019 · $220,731 — Project Abstract The blossoming diabetes, obesity and metabolic syndrome epidemics have taken a toll on the North American liver. The incidence and prevalence of non-alcoholic fatty liver disease (NAFLD), whose genesis is in simple steatosis, and non-alcoholic steatohepatitis (NASH), are staggering.…
Eryn E. Dixon · UNIVERSITY OF MARYLAND BALTIMORE · 2019 · $37,082 — Project summary/abstract The mechanism of cystogenesis in autosomal dominant polycystic kidney disease (ADPKD) remains ambiguous. While many altered signaling pathways have been identified as part of cyst formation, very little is known about the downstream effects of loss of function mutations in …
Lanying Du · NEW YORK BLOOD CENTER · 2019 · $821,329 — Abstract Traditional strategies of vaccine development suffer from long-term and costly manufacture, and as a result, often fail to respond rapidly to newly emerging and reemerging infectious diseases. By contrast, messenger RNA (mRNA) is rising as a new technology platform to develop vaccines “on d…
Jixin Zhong · CASE WESTERN RESERVE UNIVERSITY · 2019 · $77,000 — ABSTRACT DPP4 inhibitors (DPP4i) are a novel class of oral anti-diabetic drugs that modulate blood glucose by suppressing DPP4-mediated enzymatic degradation of insulinotropic incretin hormones. However, the non- enzymatic function of DPP4 in diabetes is not well understood. Recent data by us and ot…